| Market Capitalization (Millions $) |
2,514 |
| Shares
Outstanding (Millions) |
378 |
| Employees |
43 |
| Revenues (TTM) (Millions $) |
142 |
| Net Income (TTM) (Millions $) |
-146 |
| Cash Flow (TTM) (Millions $) |
77 |
| Capital Exp. (TTM) (Millions $) |
8 |
Business Description
Nuvation Bio Inc. is a biopharmaceutical company that specializes in the research, development, and delivery of innovative therapies for the treatment of chronic diseases. The company's mission is to improve the lives of patients by creating transformative medicines that address unmet medical needs.
Nuvation Bio's primary focus is on the development of a new class of drugs known as engineered decoy receptors. These drugs are designed to target the root cause of chronic diseases by neutralizing specific proteins in the body that contribute to disease progression. By doing so, the company hopes to provide patients with more effective and durable treatments that have fewer side effects than traditional drugs.
The company was founded in 2018 by several renowned scientists and biotech entrepreneurs, including Dr. George Gilliland and Dr. Robert Tjian. Dr. Gilliland is a leading expert in protein engineering and has led the development of several successful biotech companies, while Dr. Tjian is a renowned biochemist and former president of the Howard Hughes Medical Institute.
Since its inception, Nuvation Bio has made significant progress in the development of its platform technology and drug candidates. The company recently announced promising preclinical data for its lead program, NB-101, which targets a protein involved in the development of fibrotic diseases.
In addition to its internal drug development efforts, Nuvation Bio has established several partnerships and collaborations with other leading biopharmaceutical companies. These relationships provide the company with access to new technologies and expertise, which it can leverage to accelerate the development of its pipeline.
Overall, Nuvation Bio Inc. is an innovative biopharmaceutical company that is well-positioned to make a significant impact in the field of chronic disease treatment. The company's platform technology and pipeline of drug candidates hold great promise for improving the lives of millions of patients worldwide.
Company Address: 1500 Broadway New York 10036 NY
Company Phone Number: 208-6102 Stock Exchange / Ticker: NYSE NUVB
|
0.000%
1.75% 
92.98 %